Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q1 2018 · 10-Q
Revenue$117.80M$117.80M+0.8% vs Q1 2017 Net Income-$4.90M-$4.90MN/M vs Q1 2017 EPS Diluted-$0.10-$0.10N/M vs Q1 2017 Gross Profit-$9,500,000N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flow-$1,000,000N/M Free Cash Flowderived-$12,600,000N/M Margins · derivedGross margin-8.1%−20.8 pt vs Q1 2017
Operating margin-8.1%−20.8 pt vs Q1 2017
Net margin-4.2%−13.1 pt vs Q1 2017
ended Mar 31, 2018 · filed May 4, 2018 · 34 d after period end